Only ‘GOOP subscribers’ would buy data for Biogen Alzheimer’s drug, analyst writes in scathing note
In a note to investors, Baird analyst Brian Skorney harshly criticized Biogen's decision to seek FDA approval for aducanumab, an amyloid beta-targeting drug whose development it had previously halted after an analysis indicated its clinical trials would fail.